Drug Target Review

AUGUST 29, 2024

MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs. What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Vial

DECEMBER 5, 2023

Next-generation sequencing (NGS) has revolutionized scientific research and clinical genomics due to high-throughput multiplexing and shed light on genome structure, function, and dynamics. It has become a fundamental tool for researchers to explore the complexities of genetic information and conduct genetic-informed drug development.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

The Pharma Data

OCTOBER 15, 2020

The findings were presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation. Researchers found an 18% relative improvement in overall survival in the recent cohort, indicating an associated benefit to placing Impella pre-PCI. This press release features multimedia. The Impella 2.5,

Hospitals 52

Hospitals FDA Approval FDA Treatment 52

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. Asia, and Europe.

Drug Development 52

Drug Development Treatment Drugs FDA Approval 52

Drug Target Review

JULY 5, 2024

Recently, a network-based drug-screening platform has been developed to test FDA-approved drugs for Alzheimer’s disease (AD) using 1,300 iPSC-derived organoids from 11 sporadic AD patients. 545:54-59 (2017). A significant challenge for the field is incorporating 3D models into high-throughput platforms. Molecular Autism.

Drugs 64

Drugs Targeted Protein Degradation Disease FDA Approval 64

NIH Director's Blog: Drug Development

JULY 20, 2017

The first genetic mutation that causes CF was discovered by a collaborative effort between my own research lab at the University of Michigan, Ann Arbor, and colleagues at the Hospital for Sick Children in Toronto—more than 25 years ago [1]. Cystic Fibrosis Foundation News Release, July 18, 2017. First, a bit of history!

Clinical Trials 52

Clinical Trials Small Molecule Disease Therapies 52

Drug Target Review

AUGUST 3, 2023

Engaging patient groups and recruiting participants for preclinical research studies remains a major challenge, as the necessary infrastructure for matchmaking and follow-up is still in its early stages. Still a big problem with today’s preclinical research methods is engaging patient groups and recruiting people to take part.

DNA 52

DNA Clinical Trials Trials Disease 52

Vial

JUNE 12, 2024

Utilizing PROs enables the active participation of patients in their care outcomes – both in a clinical setting and in clinical research. While PROs may not have unconditional acceptance and wide use in clinical research across all therapeutic areas, they have been in use for over a decade in some. For HF, Savarese et al.

Clinical Trials 52

Clinical Trials Trials FDA Clinical Research 52

The Pharma Data

JANUARY 31, 2021

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. About Clover Biopharmaceuticals. For more information, visit www.dynavax.com.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Drug Target Review

DECEMBER 5, 2024

Among them, adeno-associated viruses (AAVs) stand out due to their small size, high efficiency in gene delivery, low immunogenicity, and potential for customisable tissue targeting, making them the leading tool in gene expression research.

Therapies 52

Therapies Virus DNA Compliance 52

New Drug Approvals

AUGUST 26, 2023

Zuranolone CAS 1632051-40-1 Zurzuvae FDA APPROVED 8/4/2023, To treat postpartum depression Press Release WeightAverage: 409.574 Monoisotopic: 409.272927379Chemical FormulaC 25 H 35 N 3 O 2 SAGE 217 SAGE-217 SAGE217 Zuranolone , sold under the brand name Zurzuvae , is a medication used for the treatment of postpartum depression. [1]

FDA 52

FDA FDA Approval Clinical Trials Treatment 52

The Pharma Data

JUNE 18, 2021

BOTOX ® Cosmetic is the first and only product of its kind FDA-approved to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow’s feet in adults. Department of Health and Human Services FDA Approval Letter for BOTOX® Cosmetic for Glabellar Lines, 2002.

Doctors 52

Doctors FDA Approval Treatment Production 52

The Pharma Data

DECEMBER 3, 2020

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. About Clover Biopharmaceuticals. For more information, visit www.dynavax.com.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

DECEMBER 15, 2020

Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The researchers regulated the abnormal immunological memory processes found in these patients. Daratumumab already is approved for the treatment of multiple myeloma. It may be life-threatening.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. In 2017, the first year of the PDUFA VI agreement under the FDA Reauthorization Act, the fees were published on September 14, 2017.

FDA 40

FDA Government Drugs Production 40

The Pharma Data

SEPTEMBER 2, 2020

New Phase III data from SAkuraStar and SAkuraSky studies demonstrate reduced severity of relapses with ENSPRYNG (satralizumab), recently FDA-approved as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52

The Pharma Data

APRIL 8, 2021

FDA and global approvals for our groundbreaking therapies in SMA and NMOSD, Roche’s data at AAN reflect our continued commitment to meaningful therapeutic progress for people living with neurological disorders,” said Levi Garraway, M.D., P15: MS Health Care System/Policy Based Research. Claims Database. Europe and Japan.

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

Broad Institute

MAY 21, 2025

The Merkin Prize recognizes novel technologies that have improved human health and is administered by the Broad Institute, one of the worlds leading biomedical research institutes. Some researchers suspected that the body would attack and destroy the CAR T cells. Their work puts us on the doorstep of finding cures to help millions.

Therapies 119

Therapies FDA Approval Engineering Immune Response 119

Practical Cheminformatics

AUGUST 3, 2023

Many papers I’ve read recently use the MoleculeNet dataset, released by the Pande group at Stanford in 2017, as the “standard” benchmark. Clintox – This dataset consists of 1483 SMILES strings and two binary labels indicating whether a molecule is an FDA-approved drug and whether a toxicity outcome has been reported.

Drugs 84

Drugs Biochemical Assays Metabolic Stability Screening Hits 84

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. CHPA supplemented the FDA’s presentation on retail volume with survey results on consumer preferences.

Science 40

Science FDA Clinical Trials Clinical Pharmacology 40

The Pharma Data

SEPTEMBER 10, 2021

“Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.” About BOTOX ® BOTOX ® was first approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults.

Doctors 52

Doctors Clinical Trials Disease Treatment 52

Codon

JUNE 5, 2025

The treatment, now known as Casgevy, became the first CRISPR-based therapy to gain FDA approval, in 2023. Researchers have since discovered variants of the protein with additional useful qualities. Researchers have also discovered a slew of small Cas9s — some less than half the size of the S.

DNA 78

DNA RNA Clinical Trials Engineering 78

Broad Institute

OCTOBER 11, 2023

Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.

Research 137

Research Immune Response Clinical Trials Therapies 137

Drug Target Review

JUNE 21, 2023

The modest sample sizes which are typical in rare disease research make it inherenttly challenging to obtain sufficient power to confidently associate gene variants to phenotypes. 14 In particular in baker’s yeast, researchers could systematically identify gene-gene interactions, including genetic suppressors.

Disease 111

Disease Clinical Trials Therapies Science 111

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today’s FDA approval, the U.S.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

NOVEMBER 15, 2020

However, doctors are continuing to prescribe the drugs “off-label” for kids with conditions like attention deficit hyperactivity disorder (ADHD), anxiety, depression and conduct disorders, the research found. Food and Drug Administration approval for this off-label usage, according to the study.

FDA Approval 52

FDA Approval Doctors Treatment Therapies 52

The Pharma Data

AUGUST 25, 2020

“AML is one of the most difficult-to-treat blood cancers, and we’re committed to furthering our research and improving on the standards of care for patients living with this aggressive disease.”. In August 2017, Bristol Myers Squibb received full approval in the U.S. Food and Drug Administration (FDA)-approved test.

Trials 52

Trials FDA Approval Therapies Treatment 52

Agency IQ

MAY 17, 2024

The bill is effectively a successor to the RACE for Children Act of 2017, which became law as part of the FDA Reauthorization Act of 2017 (FDARA). However, the FDA then approved another amifampridine product, Ruzurgi, in 2019 for the treatment of LEMS in pediatric patients. DORIS MATSUI (D-Calif.)

FDA 40

FDA Disease FDA Approval Production 40

The Pharma Data

AUGUST 22, 2021

a CheckMate -274 primary investigator and Professor of Medicine, Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer, and Associate Director for Translational Research at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. Galsky,* M.D., About CheckMate -274.

FDA Approval 52

FDA Approval Disease Treatment Drugs 52

The Pharma Data

JANUARY 21, 2021

The 2021 finalists were selected from 1,760 highly qualified entrants, all of whom completed an original research project and extensive application process. Each year, around 2,000 student entrants submit original research in critically important scientific fields of study and are judged by leading experts in their fields.

Science 40

Science Engineering Molecular Biology Bioinformatics 40

Agency IQ

JUNE 2, 2023

FDA unveils long-awaited Patient Medication Information proposed rule Since 2017, the FDA has been working on a proposal to create a new type of patient-focused labeling for certain outpatient drug products that would be specifically targeted for patient use.

FDA 40

FDA FDA Approval Production Regulations 40

The Pharma Data

JUNE 18, 2021

” The pivotal Phase 3 RESONATE-2 study served as the basis for the FDA approval of IMBRUVICA as a single-agent in first-line treatment for CLL/SLL in 2016, following initial approval for relapsed/refractory (R/R) patients in 2014 based on the RESONATE study. 2.2017 were used given 74 percent enrollment in 2017.

FDA Approval 40

FDA Approval Treatment Therapies FDA 40

The Pharma Data

MARCH 11, 2021

In 2017, Opdivo was granted accelerated approval by the FDA as a single agent for patients with HCC who have been previously treated with sorafenib. The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

JULY 23, 2021

We took this action following the Agency’s industry-wide evaluation of accelerated approvals for checkpoint inhibitors that have not met their post-marketing requirements demonstrating confirmatory benefit. This included a meeting of the Oncologic Drugs Advisory Committee in April and subsequent discussion with the FDA.

Treatment 52

Treatment Trials Therapies Disease 52

The Pharma Data

MARCH 16, 2021

Food and Drug Administration (FDA) approved Evrysdi for the treatment of SMA in adults and children 2 months of age and older in August of 2020. Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively.

Pharmacokinetics 52

Pharmacokinetics Treatment Clinical Trials Disease 52

The Pharma Data

MARCH 16, 2021

Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC. TREMFYA was approved in the U.S. for the treatment of adults with moderate to severe plaque PsO in July 2017 and in July 2020 for adults with active PsA. TREMFYA q4w is not currently FDA-approved.

Treatment 52

Treatment Disease Pharmacokinetics Therapies 52

New Drug Approvals

JULY 10, 2023

If FDA approved, it will join other previously-approved “-gepant” drugs [ rimegepant ] and [ ubrogepant ] as an additional treatment alternative for patients with migraine, particularly those for whom traditional triptan therapy has proven ineffective. Migraine is both widespread and disabling. 2021 Jan 1;31:127624.

Clinical Trials 40

Clinical Trials Treatment Trials FDA 40